Arcus Biosciences EBITDA Margin 2017-2023 | RCUS

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Arcus Biosciences (RCUS) over the last 10 years. The current EBITDA margin for Arcus Biosciences as of March 31, 2023 is .
Arcus Biosciences EBITDA Margin Historical Data
2023-03-31 $0.12B $-0.30B -248.33%
2022-12-31 $0.11B $-0.27B -242.48%
2022-09-30 $0.43B $0.09B 19.82%
2022-06-30 $0.41B $0.08B 19.07%
2022-03-31 $0.39B $0.07B 18.16%
2021-12-31 $0.38B $0.06B 16.75%
2021-09-30 $0.04B $-0.27B -735.14%
2021-06-30 $0.09B $-0.19B -207.53%
2021-03-31 $0.09B $-0.16B -190.70%
2020-12-31 $0.08B $-0.12B -153.16%
2020-09-30 $0.08B $-0.09B -110.13%
2020-06-30 $0.02B $-0.11B -706.25%
2020-03-31 $0.02B $-0.10B -606.25%
2019-12-31 $0.02B $-0.09B -550.00%
2019-09-30 $0.01B $-0.08B -1050.00%
2019-06-30 $0.01B $-0.07B -730.00%
2019-03-31 $0.01B $-0.06B -655.56%
2018-12-31 $0.01B $-0.05B -662.50%
2018-09-30 $0.01B $-0.05B -757.14%
2018-06-30 $0.00B $-0.06B -2100.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.582B $0.112B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $137.206B 8.38
GSK (GSK) United Kingdom $71.088B 9.92
Bio-Rad Laboratories (BIO.B) United States $10.988B 29.38
QIAGEN (QGEN) Netherlands $10.347B 21.85
Ginkgo Bioworks Holdings (DNA) United States $3.670B 0.00
Biohaven (BHVN) United States $1.578B 0.00
Emergent Biosolutions (EBS) United States $0.423B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.192B 0.00
Enzo Biochem (ENZ) United States $0.109B 0.00
SQZ Biotechnologies (SQZ) United States $0.016B 0.00